Trade Alector, Inc. - ALEC CFD

Alector, Inc. Company profile

About Alector Inc

Alector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The Company is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. The Company has advanced four product candidates, AL001, AL002, AL003, and AL101, into clinical development. Its first product candidate, AL001, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients. Its AL002 targets triggering receptor expressed on myeloid cells 2 (TREM2) to increase the functionality of TREM2 signaling and enhance microglia cell activation.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Alector Inc revenues increased from $21.1M to $207.1M. Net loss decreased 81% to $36.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General and administrative - Balancing decrease of 19% to $35.7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.45 to -$0.45.